Rifapentine is a cyclopentyl derivative of rifampin. It is a drug in the class rifamycins. The US CDC's Tuberculosis Trials Consoritum (TBTC)'s published results of a 4-month rifapentine-based regimen containing moxifloxacin as noninferior to the standard 6-month regimen in the treatment of tuberculosis.
Compound
Rifapentine
CDC TBTC, Sanofi
Names
Priftin
Chemical Class:
Rifamycin
Description
Related Links
Trial Associations